This finding is consistent with the results of a report from JAMA Oncology, which concluded that MUC16 mutations were associated with increased numbers of mutations in tumors together with better survival outcomes in GC patients (Li et al., 2018). The gene discussed is MUC16; the disease is gastric cancer.